



RECEIVED

NOV 28 2001

GAU/1645  
#3

TECH CENTER 1600/2900

**IN THE UNITED STATES PATENT AND TRADEMARK**

Applicant:	ALLEN	Examiner:	Unassigned
U.S.S.N.:	09/903,377	Group Art Unit:	1645
Filed:	July 10, 2001	Docket:	R-365
For:	TRANSGENIC MICE CONTAINING CHEMOKINE RECEPTOR 9A GENE DISRUPTIONS		

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Attached is a Form PTO-1449 listing each of the enclosed documents.


This Information Disclosure Statement ("IDS") is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is respectfully requested, along with additional time under Rule 97(f), to enable Applicant to fully comply.

Should a first Office Action on the merits have been issued on the same day or before this IDS is filed, please accept this IDS under Rule 97(c) and charge the requisite fee under Rule 17(p) to our Deposit Account No. 50-1271, Order No. R-365 and proceed to consider this Information Disclosure Statement.

Consideration of the foregoing and enclosures, the return of a copy of the enclosed Form PTO-1449 with the Examiner's initials in the left column, and an action on the merits of this application are respectfully requested.

Respectfully submitted,  
DELTAGEN, INC.

20 Nov. 2001  
Date  
740 Bay Road  
Redwood City, CA 94063

*for*  (Reg. No. 47,536)  
Jane K. Babin  
Reg. No. 47,224  
Phone: 650/569-5100